Overview
- Peptide NKSLSSFKENEENIQC, corresponding to amino acid residues 84-99 of rat CB1 receptor (Accession P20272). Extracellular, N-terminus.
Cell surface detection of CB1 receptor in live intact human THP-1 monocytic leukemia cells:___ Cells.
___ Cells + rabbit IgG isotype control-FITC.
___ Cells + Anti-Cannabinoid Receptor 1 (extracellular)-FITC Antibody (#ACR-001-F), (2.5 µg).
Cell surface detection of CB1 receptor in live intact mouse P815 mastocytoma cell line:___ Cells.
___ Cells + rabbit IgG isotype control-FITC.
___ Cells + Anti-Cannabinoid Receptor 1 (extracellular)-FITC Antibody (#ACR-001-F), (5 µg).
- Howlett, A.C. (2002) Prostaglandins Other Lipid Mediat. 68, 619.
- Guo, J. and Ikeda, S.R. (2004) Mol. Pharmacol. 65, 665.
- Wotherspoon, G. et al. (2005) Neuroscience 135, 235.
- Gong, J.P. et al. (2006) Brain Res. 1071, 10.
- Fernandez-Ruiz, J. et al. (2007) Trends Pharmacol. Sci. 28, 39.
- Sarfaraz, S. et al. (2005) Cancer Res. 65, 1635.
- Sanchez, C. et al. (2001) Cancer Res. 61, 5784.
- Alberich Jorda, M. et al. (2004) Blood 104, 526.
Cannabinoids have been used in Eastern medicine for many years as pain relievers. Δ9-tetrahydrocannabinol (THC), the major psychoactive compound in marijuana and hashish, has been shown to interact with two specific cannabinoid receptors: cannabinoid receptor 1 (CB1 receptor) and cannabinoid receptor 2 (CB2 receptor).1 The cannabinoid receptors can be distinguished by their amino acid sequences, signaling mechanisms, and tissue distributions.1 Both receptors belong to the G-protein coupled receptor (GPCR) superfamily. CB1 was shown to modulate several Ca2+ and K+ ion channels.1,2
CB1 is primarily expressed in the central nervous system. However, expression of CB1 is also detected in the peripheral terminals, in non-neuronal peripheral tissues such as uterus, testes, spleen, as well as in cells of the immune system.2,3
CB1 is implicated in many cellular functions such as neurotransmitter release, pain relief, cancer, and obesity.4,5 Growth inhibition of tumor cells was demonstrated following mixed CB1/CB2 agonist treatment in both prostate and non-melanoma skin cancers.4,5 Through their interaction with CB1, cannabinoid compounds stimulate appetite for sweets and palatable foods in particular, making CB1 an attractive therapeutic target for the treatment of obesity and eating disorders.6
Anti-Cannabinoid Receptor 1 (extracellular) Antibody (#ACR-001) is a highly specific antibody directed against an epitope of the rat CB1 receptor. The antibody can be used in western blot, immunohistochemistry, and live cell imaging applications. It has been designed to recognize CB1 in human, mouse, and rat samples.
Anti-Cannabinoid Receptor 1 (extracellular)-FITC Antibody (#ACR-001-F) is directly conjugated to fluorescein isothiocyanate (FITC). This labeled antibody can be used in immunofluorescent applications such as direct live cell flow cytometry.
Powered by Bioz